Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform.

The idea is to combine desirable structural features from different protein family members to generate libraries of candidate therapies with optimized potency, pharmacodynamics, shelf life and protein expression. Prosit Sole will deploy the libraries in functional screens, Director, Founder and CEO Hongyu Liu told BioCentury...